Особенности применения нестероидныхпротивовоспалительных препаратов при спондилоартритах

1. Amor B, Dougados M, Mijiyawa M. Criteres de classification des spondiloarthropaties. Rev Rhum 1990; 57: 85–9.
2. van der Linden S, Valkenburg H, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361–8.
3. Khan MA. A double blind comparison of diclofenac and indometacin in the treatment of ankylosing spondylitis. J Rheumatol 1987; 14: 118–23.
4. Braun J, Pham T, Sieper J et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 62: 817–24.
5. van der Heijde D et al. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol 1999; 26: 951–4.
6. Boersma JW. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazon. Scand J Rheumatol 1976; 5: 60–4.
7. Wanders A, Van der Heijde D, Landewe R et al. Nonsteroidal anti– inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis. Arthritis Rheum 2005; 52: 1756–65.
8. Song IH, Poddubnyy DA, Rudwaleit M, Sieper J. Benefits and Risks of Ankylosing Spondylitis Treatment with Nonsteroidal Anti-inflammatory Drugs. Arthr & Rheum 2008; 58: 929–38.
9. van der Heijde D, Baraf HSB, Ramos-Remus C et al. Evalution of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005; 52: 1205–15.
10. Laine L, Curtis SP, Cryer B et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised controlled trial. Lancet 2007; 369: 465–73.
11. Бурдейный А.П. Методы оценки и эффективность современных и противовоспалительных и иммуномодулирующих препаратов при болезни Бехтерева. Автореф. ... дис. канд. мед. наук. М., 1990.
12. Sturrock DS, Dudley F. Double-blind coss-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis. Ann Rheum Dis 1974; 33: 129.
13. Daugados M et al. Ximoprophen in ankylosing spondylitis. Scand J Rheum 1994; 23: 245–8.
14. Zhang X, Schwarz EM, Young DA et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Ivest 2002; 109: 1405–15.
15. Dougados М, Gueguen A, Nakache JP et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford) 1999; 38: 235–44.
16. Gabriel SE, Jaakkimainen I, Bombardier C. Risk for serious gastrointestitinal complications relatd to use of nonsteroidal anti-inflammatory drugs: a meta-analisis. Ann Intern Med 1991; 115: 787–96.
17. Miedany EI, Youssef S, Ahmed I, Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 751–7.
18. Dougados M, Behier JM, Jolchine I et al. Efficacy of Celecoxib, a Cyclooxygenase 2-Specific Ingibitor, in the Treatment of Ankylosing Spondylitis. Arthr Rheum 2000; 44: 180–5.
19. Rudwaleit M, Niewerth M, Listing J et al. Disease activity over one year in early ankylosing spondylitis in a prospective observational cohort (GESPIC) (abstract). Ann Rheum Dis 2005; 64 (suppl. III): 65.
20. Barkhuizen A, Steinfeld S, Robbins J et al. Celecoxib is efficacious and well tolerated in treating sings and symptoms of ankylosing spondylitis. J Rheumatol 2006; 33: 1805–12.
21. Sieper J, Klopsch T, Richter M et al. Comparison of 2 different dosages of celecoxib with diclofenac for the treatment of active AS: results of a 12-week randomized double-blind controlled study. Ann Rheum Dis 2008; 67 (3): 323–9.